The efficacy and tolerability of mirabegron, a potent and selective ß3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder – results from a European–Australian Phase III trial

Khullar V1, Cambronero J2, Stroeberg P3, Angulo J4, Boerrigter P5, Wooning M6

Abstract Category

Detrusor Overactivity

Abstract 328
Non-Discussion Posters
Scientific Non Discussion Poster Session 29
1. St Mary's Hospital, Imperial College, Urogynaecology Department, London, UK, 2. Infanta Leonor Hospital, Department of Urology, Madrid, Spain, 3. American Hospital Dubai, Department of Urology, Dubai, United Arab Emirates, 4. Hospital Universitario de Getafe, Department of Urology, Madrid, Spain, 5. Astellas Pharma Global Development-EU, Medical Science department, Leiderdorp, The Netherlands, 6. Astellas Pharma Global Development, Clinical research, Leiderdorp, The Netherlands